Altogether, these results suggested that KHAG-04 can lower the conditions of NAFLD and inflammation in the liver by reducing the level of NAFLD and pro-inflammatory biomarkers such as CRP, IL-6, and TNF-α. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.